ITUS - ITUS Corporation

YHD - YHD Delayed Price. Currency in USD
At close: 6:07PM EDT
Stock chart is not supported by your current browser
Previous CloseN/A
YTD ReturnN/A
Expense Ratio (net)N/A
CategoryN/A
Last Cap GainN/A
Morningstar RatingN/A
Morningstar Risk RatingN/A
Sustainability RatingN/A
Net AssetsN/A
Beta (3Y Monthly)N/A
YieldN/A
5y Average ReturnN/A
Holdings TurnoverN/A
Last DividendN/A
Average for CategoryN/A
Inception DateN/A
  • ITUS Corporation Changing Company Name to Anixa Biosciences and Stock Ticker Symbol to ANIX
    PR Newswire

    ITUS Corporation Changing Company Name to Anixa Biosciences and Stock Ticker Symbol to ANIX

    SAN JOSE, Calif., Sept. 28, 2018 /PRNewswire/ -- ITUS Corporation (the "Company") (ITUS), a biotechnology company focused on using the body's immune system to fight cancer, today announced that on October 1, 2018, the Company will officially change its name to Anixa Biosciences, Inc.  Effective at the start of trading on October 1, 2018, the Company's shares will trade on the NASDAQ Capital Market under the new name, and the new stock symbol will be "ANIX."  The Company's website will be accessible at www.anixa.com.

  • GuruFocus.com

    Weekly CFO Buys Highlight

    Insiders invest in ITUS, Energy Transfer Partners and PolarityTE

  • Moffitt Cancer Center and ITUS Corporation Announce Scheduling of Pre-IND Meeting with the FDA for their CAR-T Therapy
    PR Newswire

    Moffitt Cancer Center and ITUS Corporation Announce Scheduling of Pre-IND Meeting with the FDA for their CAR-T Therapy

    SAN JOSE, Calif., Sept. 5, 2018 /PRNewswire/ -- ITUS Corporation (ITUS) and its research partner, Moffitt Cancer Center, today announced that a pre-IND meeting with the US FDA has been scheduled on Tuesday, October 16, 2018.  The meeting is to discuss numerous aspects of the planned clinical trial of their CAR-T therapy for ovarian cancer. Dr. Amit Kumar, CEO of ITUS stated, "We are pleased to be meeting with the FDA this fall, as anticipated.  We have submitted pre-clinical data, as well as a series of questions, to the FDA.  Coming out of this meeting, our goal is to have a good understanding of the design for the clinical trial in our Investigational New Drug (IND) application.